PUBLISHER: DelveInsight | PRODUCT CODE: 1096496
PUBLISHER: DelveInsight | PRODUCT CODE: 1096496
DelveInsight's, "Chemotherapy Induced Neutropenia - Pipeline Insight, 2022," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chemotherapy Induced Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chemotherapy Induced Neutropenia Understanding
Chemotherapy Induced Neutropenia: Overview
Chemotherapy-induced neutropenia (CIN) is one of the most common side effects seen in cancer patients. As an adverse event, it is deemed undesirable since it often constitutes a dose-limiting toxicity for cytotoxic agents leading to treatment delays and/or dose reductions. It is also associated with a financial cost component from diagnostic work-up and treatment of patients with chemotherapy-induced febrile neutropenia (CIFN). Neutropenia is commonly accompanied by a decrease in other hematopoietic lineages (anemia and/or thrombocytopenia). Dosing of chemotherapeutic agents is based on the severity of adverse effects seen. Depending on the degree of neutropenia, chemotherapeutic agents may be put on hold until count recovery and growth factor support might be added to allow for dosing as scheduled. However, neutropenia appears to be more than just an adverse event. While CIFN by itself constitutes an adverse event, the appearance of just CIN is not necessarily a marker of poor outcome. In fact, it rather appears to be a surrogate marker of response and/or survival in patients treated with cytotoxic regimens.
"Chemotherapy Induced Neutropenia - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Neutropenia pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Neutropenia treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Neutropenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Neutropenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Chemotherapy Induced Neutropenia Emerging Drugs Chapters
This segment of the Chemotherapy Induced Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chemotherapy Induced Neutropenia Emerging Drugs
ALRN-6924 is a novel medicine designed to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects without interrupting chemotherapy's destruction of cancer cells.
EC-18 was developed over two decades of research by Drs. Changgi D. Hong and Sang-Hee Kim at Asan Medical Center in Seoul. EC-18 is Enzychem's leading compound, which is a proprietary compound originally derived from Sika deer antler. After the initial research on this unique compound, Enzychem Lifesciences conducted an additional six years of research on EC-18 to fully synthesize the compound and to be equipped with mass production capability. Based on our findings from preclinical and clinical studies, Enzychem Lifesciences is developing EC-18 for indications including chemoradiation induced oral mucositis (CRIOM), chemotherapy induced neutropenia (CIN), acute radiation syndrome (ARS), acute respiratory distress syndrome associated with COVID-19, Immune Checkpoint Inhibitors (ICI), and Non-alcoholic Steatohepatitis (NASH).
Further product details are provided in the report……..
Chemotherapy Induced Neutropenia: Therapeutic Assessment
This segment of the report provides insights about the different Chemotherapy Induced Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Chemotherapy Induced Neutropenia. The companies which have their Chemotherapy Induced Neutropenia drug candidates in the most advanced stage, i.e. phase II include, Enzychem Lifesciences.
DelveInsight's report covers around 3+ products under different phases of clinical development like
Chemotherapy Induced Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chemotherapy Induced Neutropenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Neutropenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Neutropenia drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Chemotherapy Induced Neutropenia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chemotherapy Induced Neutropenia - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
EC-18: Enzychem Lifesciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ALRN-6924: Aileron Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Chemotherapy Induced Neutropenia Key Companies
Chemotherapy Induced Neutropenia Key Products
Chemotherapy Induced Neutropenia- Unmet Needs
Chemotherapy Induced Neutropenia- Market Drivers and Barriers
Chemotherapy Induced Neutropenia- Future Perspectives and Conclusion
Chemotherapy Induced Neutropenia Analyst Views
Chemotherapy Induced Neutropenia Key Companies
Appendix